February 23, 2007 -- Roche and Genentech reported new indications were approved in Europe for Avastin and Xoloda; Dynavax said Tolamba was unable to show efficacy against ragweed because its incidence was too low in the placebo; Pfizer won a preliminary injunction in Denmark against a generic version of Lipitor; Idenix won recommendation in Europe for approval of Sebivo, a hepatitis B drug; Pharmion and GPC Biotech are presenting positive data on satraplatin for prostate cancer; Peregrine said its tumor necrosis therapy technology was starting clinical trials in Europe by an unnamed licensee; UCB reported a Phase III trial showed Cimzia was effective against rheumatoid arthritis; and Amgen rose, then fell, following news that Roche would suspend trials of an anemia drug. The Centient Biotech 200™ dropped two points today to 4055, a slide of .04%, but it was up 1 point for the entire week. More details...
